Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luis Hernandez Rosado

Internal Medicine Pinecrest, FL Medical Doctor

NPI 1144527466 CMS profile 188077

12780 Sw 71St Ave, Pinecrest, FL 33156

Open in the dashboard

General payments

$875

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,460,800 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Luis Hernandez Rosado of Pinecrest, FL is reported in the CMS Open Payments database as having received $875 across 27 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,460,800 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $62 1
2023 General $104 3
2021 General $211 3
2020 General $144 8
2019 General $353 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Hernandez Rosado
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Luis Hernandez Rosado were reported at $62. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Luis Hernandez Rosado Internal Medicine median Middle half National median
2019 $353 $159 $48–$570 $163
2020 $144 $119 $33–$402 $114
2021 $211 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $104 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $62 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $229 9 payments
  2. Abbott Laboratories $228 8 payments
  3. E.R. Squibb & Sons, L.L.C. $98 1 payment
  4. Intuitive Surgical, Inc. $90 1 payment
  5. PolyNovo North America LLC $62 1 payment
  6. Kiniksa Pharmaceuticals, Ltd. $37 1 payment
  7. Mallinckrodt Hospital Products Inc. $36 1 payment
  8. Pfizer Inc. $35 2 payments
  9. Lilly USA, LLC $30 1 payment
  10. Baudax Bio Inc. $17 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $875 27 payments
Products named General payments · program years 2019–2025
  1. XARELTO $229 9 payments
  2. CardioMEMS HF System $123 7 payments
  3. EnSite X $104 1 payment
  4. ELIQUIS Cardiovascular $98 1 payment
  5. Da Vinci Surgical System $90 1 payment
  6. NOVOSORB BTM $62 1 payment
  7. Arcalyst $37 1 payment
  8. ACTHAR $36 1 payment
  9. ELIQUIS Cardiovascular;Metabolic Disease $35 2 payments
  10. VYNDAQEL $35 2 payments
  11. Other $60 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

569

Median for Internal Medicine: 777

Drug cost

$48,600

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 23 $14,291
Entresto Sacubitril/Valsartan Brand 16 $11,616
Eliquis Apixaban Brand 19 $10,728
Brilinta Ticagrelor Brand 20 $8,764
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $539
Amiodarone Hcl Generic 21 $437
Rosuvastatin Calcium Generic 63 $290
Bumetanide Generic 16 $238
Nifedipine Er Nifedipine Brand 16 $225
Pantoprazole Sodium Generic 32 $178

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$381,412

Medicare's payments for the services billed

Medicare patients

747

Average age 78

Services billed

5,123

424 women, 323 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 56%
Ischemic heart disease 54%
Chronic kidney disease 49%
Heart failure 48%
Depression 47%
Alzheimer's or dementia 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record